Idera Pharmaceuticals Inc  

(Public, NASDAQ:IDRA)   Watch this stock  
Find more results for IDRA
2.84
-0.05 (-1.73%)
Real-time:   9:58AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.82 - 2.89
52 week 1.93 - 5.48
Open 2.85
Vol / Avg. 44,218.00/1.80M
Mkt cap 335.47M
P/E     -
Div/yield     -
EPS -0.48
Shares 118.12M
Beta 2.61
Inst. own 52%
Nov 5, 2015
Q3 2015 Idera Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 11, 2015
Idera Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference
Aug 6, 2015
Q2 2015 Idera Pharmaceuticals Inc Earnings Release
Jun 24, 2015
Idera Pharmaceuticals, Inc. at JMP Securities 2015 Life Sciences Conference - Webcast
Jun 1, 2015
Idera Pharmaceuticals, Inc. at Jefferies 2015 Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -254380.00% -52934.25%
Operating margin -255520.00% -53084.93%
EBITD margin - -52802.74%
Return on average assets -44.33% -87.53%
Return on average equity -47.29% -120.75%
Employees 45 -
CDP Score - -

Address

167 Sidney St
CAMBRIDGE, MA 02139-4237
United States - Map
+1-617-6795500 (Phone)
+1-617-6795592 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company uses two drug discovery technology platforms to design and develop drug candidates. Using its Toll-like receptor (TLR) targeting technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its gene silencing oligonucleotide (GSO) technology, the Company is developing GSOs to turn off the messenger RNA (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400 for Waldenstrom's macroglobulinemia and diffuse large B-Cell lymphoma; IMO-2055/IMO-2125 for immune-oncology; IMO-8400 for dermatomyositis and Duchenne Muscular Dystrophy (DMD), and IMO-9200 for selected autoimmune disease.

Officers and directors

James A. Geraghty Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Vincent J. Milano President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Youssef El Zein Independent Vice Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Louis J. Arcudi III Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary
Age: 54
Bio & Compensation  - Reuters
Robert Clayton Fletcher Senior Vice President - Business Development and Strategic Planning
Age: 52
Bio & Compensation  - Reuters
Robert A. Doody Jr. Vice President - Investor Relations and Corporate Communications
Bio & Compensation  - Reuters
William S. Reardon CPA Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Sudhir Agrawal D. Phil. Director, President of Research
Age: 61
Bio & Compensation  - Reuters
Julian C. Baker Independent Director
Age: 49
Bio & Compensation  - Reuters
Mark A Goldberg M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters